PRDX1-IN-4

PRDX1-IN-4 (derivative 5) (20 mg/kg; i.p.; single administration; 14-day observation period) causes no mortality in the acute toxicity model of wild-type male C57BL/6 mice. It induces no significant body weight loss or histopathological damage in the heart, liver, spleen, lung or kidney, and no abnormalities in serum ALT, AST levels or red blood cell counts. Its safety is significantly superior to that of celastrol at the same dose^[1].
PRDX1-IN-4 (1 mg/kg; intraperitoneal injection; once daily for 4 consecutive weeks, starting from the 3rd week of modeling) significantly ameliorates CCl₄-induced liver injury and fibrosis in the CCl₄-induced hepatic fibrosis model of male C57BL/6 mice. It reduces the liver/body weight ratio, serum ALT and AST levels, and collagen fiber deposition, downregulates the expressions of α-SMA and COL1A1 in liver tissues, and inhibits NLRP3 inflammasome activation. No mouse death is observed, and its safety is superior to that of celastrol at the same dose^[1].